PDCD1 and neoplasm: Tumor-infiltrating cells with a TRM phenotype from advanced melanoma and lung cancer patients express higher inhibitory receptors such as PD-1, Tim3, and LAG3, which opens up the possibility that checkpoint blockade might promote the greater anti-tumor immunity by TRM cells (177, 179, 180).